SCHEMBL22557510

SCHEMBL22557510

COC(=O)c1ccccc1-n1cc(N)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.50
ALDH1A1 P00352 3/20 0.49
HSD17B10 Q99714 2/20 0.49
CFTR P13569 1/20 0.49
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 3/20 0.43
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.42
POLB P06746 3/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA5A P35218 1/20 0.41
CA9 Q16790 1/20 0.41
GLA P06280 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28405986 0.80 L3MBTL1 (0.46) MYCALDH1A1HSD17B10CYP1A2SMN1; SMN2
SCHEMBL22556864 0.79 F2 (0.50) MYCALDH1A1HSD17B10CYP2C9CYP2C19
SCHEMBL27787386 0.75 MYC (0.54) MYCALDH1A1HSD17B10CFTRKMT2A
SCHEMBL28536420 0.74 MYC (0.50) MYCALDH1A1HSD17B10CFTRKMT2A
SCHEMBL22633031 0.74 MTOR (0.45) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL28642575 0.74 CYP1A2 (0.56) MYCALDH1A1HSD17B10CFTRKMT2A
SCHEMBL22580254 0.72 TP53 (0.58) ALDH1A1CYP1A2CYP2C19LMNAGAA
SCHEMBL29596209 0.72 MYC (0.58) MYCALDH1A1HSD17B10CFTRSMN1; SMN2
SCHEMBL22633214 0.72 MAPK14 (0.43) ALDH1A1KMT2AMEN1SMN1; SMN2LMNA
SCHEMBL20273791 0.72 GAA (0.39) ALDH1A1HSD17B10CYP1A2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113710664-B JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2024-01-26 CN disclosed
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-07-14 US disclosed
EP-3956322-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2022-02-23 EP disclosed
CN-113710664-A JAK1 selective kinase inhibitors 迪哲(江苏)医药股份有限公司 2021-11-26 CN disclosed
WO-2020211839-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-10-22 WO disclosed
WO-2020211839-A1 JAK1 SELECTIVE KINASE INHIBITOR DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2020-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220096-A1 JAK1 SELECTIVE KINASE INHIBITOR JAK1, JAK2, JAK3 MYC 2642/4885ALDH1A1 1434/4885HSD17B10 2482/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.